Skip to content
Disclosery

AJU IB Investment Co., Ltd.

Follow

13F filer, CIK 1710065, Seoul, Korea Republic of

AJU IB Investment Co., Ltd. reported $84,044,699 across 8 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-04-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001140361-25-012676

Period
2025-03-31
Reported value
$84M
Holdings
8
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001140361-25-012676, largest first. % of portfolio is the value over $84,044,699, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 1,047,557 shares; 2025Q1: 1,047,557 shares 1,047,557$68.7M81.77%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 457,059 shares; 2025Q1: 457,059 shares 457,059$12.5M14.88%0Timeline
SEERSEER INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 816,375 shares; 2025Q1: 816,375 shares 816,375$1.38M1.64%0Timeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 754,678 shares; 2025Q1: 754,678 shares 754,678$494K0.59%0
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 667,742 shares; 2025Q1: 667,742 shares 667,742$484K0.58%0Timeline
CARMCARISMA THERAPEUTICS INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 718,332 shares; 2025Q1: 718,332 shares 718,332$223K0.26%0Timeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 99,503 shares; 2025Q1: 99,503 shares 99,503$121K0.14%0
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 175,000 shares; 2025Q1: 175,000 shares 175,000$114K0.14%0

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001140361-25-012676 base2025-04-08acceptance time not in the bulk data set